JP2008543822A5 - - Google Patents

Info

Publication number

JP2008543822A5

JP2008543822A5 JP2008516414A JP2008516414A JP2008543822A5 JP 2008543822 A5 JP2008543822 A5 JP 2008543822A5 JP 2008516414 A JP2008516414 A JP 2008516414A JP 2008516414 A JP2008516414 A JP 2008516414A JP 2008543822 A5 JP2008543822 A5 JP 2008543822A5

Authority

JP

Japan

Prior art keywords

group

pharmaceutically acceptable

acceptable salt

cycloalkyl

compound according

Prior art date

2006-06-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003839 salts Chemical class 0.000 claims 21
• 150000001875 compounds Chemical class 0.000 claims 13
• 125000000217 alkyl group Chemical group 0.000 claims 9
• -1 chloro, bromo, iodo, hydroxy Chemical group 0.000 claims 8
• 125000000753 cycloalkyl group Chemical group 0.000 claims 8
• 125000005592 polycycloalkyl group Polymers 0.000 claims 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
• 125000003342 alkenyl group Chemical group 0.000 claims 6
• 125000003545 alkoxy group Chemical group 0.000 claims 6
• 125000000304 alkynyl group Chemical group 0.000 claims 6
• 125000004103 aminoalkyl group Chemical group 0.000 claims 6
• 125000004432 carbon atom Chemical group C* 0.000 claims 6
• 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
• 125000001153 fluoro group Chemical group F* 0.000 claims 6
• 125000004438 haloalkoxy group Chemical group 0.000 claims 6
• 125000001188 haloalkyl group Chemical group 0.000 claims 6
• 229910052739 hydrogen Inorganic materials 0.000 claims 6
• 239000001257 hydrogen Substances 0.000 claims 6
• 125000005429 oxyalkyl group Chemical group 0.000 claims 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims 6
• 125000001424 substituent group Chemical group 0.000 claims 6
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
• 208000027866 inflammatory disease Diseases 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
• 239000004480 active ingredient Substances 0.000 claims 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
• 229910052799 carbon Inorganic materials 0.000 claims 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 210000000056 organ Anatomy 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 206010059245 Angiopathy Diseases 0.000 claims 1
• 208000023275 Autoimmune disease Diseases 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 206010020751 Hypersensitivity Diseases 0.000 claims 1
• 208000029725 Metabolic bone disease Diseases 0.000 claims 1
• 208000001132 Osteoporosis Diseases 0.000 claims 1
• 201000004681 Psoriasis Diseases 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
• 208000036142 Viral infection Diseases 0.000 claims 1
• 230000007815 allergy Effects 0.000 claims 1
• 230000003110 anti-inflammatory effect Effects 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 230000003111 delayed effect Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 230000028993 immune response Effects 0.000 claims 1
• 230000028709 inflammatory response Effects 0.000 claims 1
• 244000000056 intracellular parasite Species 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 230000004768 organ dysfunction Effects 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 230000037380 skin damage Effects 0.000 claims 1
• 230000001629 suppression Effects 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1
• 208000019553 vascular disease Diseases 0.000 claims 1
• 230000029812 viral genome replication Effects 0.000 claims 1
• 230000009385 viral infection Effects 0.000 claims 1